Abstract:Background: Glioblastoma multiforme (GBM) is the most lethal brain cancer in adults, characterized by rapid growth, extensive invasiveness, and poor prognosis, and there is still a lack of effective treatments. Here, we aimed to explore the role of triptolide (TPL), purified from Tripterygium wilfordii Hook F, on glioblastoma cell growth, apoptosis, proliferation, migration and invasion, as well as potential underlying mechanisms. Methods: The publicly available clinical data of Brain Lower Grade Glioma (LGG) from The Cancer Genome Atlas (TCGA) had been screened to observe PROX1 expression. The Kaplan-Meier analysis was used to analyze the relationship between PROX1 expression and GBM prognosis. CCK8, cell cycle, EDU, apoptosis, wound healing, and transwell assays were performed to detect the effects of TPL on glioblastoma U251 cell viability, cell cycle, proliferation, apoptosis, migration and invasion, respectively. Further, a soft agar colony assay was used to calculate the growth of glioblastoma cells. The qRT-PCR and western blot were conducted to quantify PROX1 mRNA and protein levels. The transcriptional regulation of TPL was detected by Dual luciferase reporter assay. Results: We found that TPL inhibited glioblastoma cell viability, proliferation, cell cycle, migration and invasion, but enhanced apoptosis in a dose-dependent manner. The expression of cell cycle inhibitor, P21, and pro-apoptosis factor, Bax was increased, while invasion-related factors MMP2 and MMP9 were silenced after TPL treatments. Mechanistically, TPL showed transcriptional inhibition of PROX1 appearance. Moreover, ectopic expression of PROX1 partially rescued the effects of TPL on glioblastoma cell viability, proliferation, apoptosis, migration and invasion, and on the expression of cell function-related genes. Conclusion: This study verified that TPL inhibited the progression of glioblastoma cells by transcriptionally depressing the expression of PROX1.

Depletion of Thymopoietin Inhibits Proliferation and Induces Cell Cycle Arrest/apoptosis in Glioblastoma Cells

Mir-138-5p Suppresses Glioblastoma Cell Viability and Leads to Cell Cycle Arrest by Targeting Cyclin D3.

Inhibition of Proliferation by Knockdown of Transmembrane (TMEM) 168 in Glioblastoma Cells Via Suppression of Wnt/β-Catenin Pathway

TMBIM1 Promotes Proliferation and Attenuates Apoptosis in Glioblastoma Cells by Targeting the P38 MAPK Signalling Pathway.

Loss of Programmed Cell Death 10 Activates Tumor Cells and Leads to Temozolomide-Resistance in Glioblastoma

Suppression of PTTG1 Inhibits Cell Angiogenesis, Migration and Invasion in Glioma Cells

Whole Transcriptome and Proteome Analyses Identify Potential Targets and Mechanisms Underlying Tumor Treating Fields Against Glioblastoma

GOLM1 Silencing Inhibits the Proliferation and Motility of Human Glioblastoma Cells Via the Wnt/β-catenin Signaling Pathway.

TMBIM1 Promotes EMT by Stimulating Autophagic Degradation of E-cadherin Via AMPK/mTOR/ULK1 Axis in Human Gliomas

Novel Biomarker Genes for Prognosis of Survival and Treatment of Glioma

Tmic-76. Prmt5 Modulates T Cell Proliferation In Glioblastoma Tumor Microenvironment

Tenacissoside H repressed the progression of glioblastoma by inhibiting the PI3K/Akt/mTOR signaling pathway

Suppressing TRAP1 sensitizes glioblastoma multiforme cells to temozolomide

Relevance of Thymic Stromal Lymphopoietin on the Pathogenesis of Glioblastoma: Role of the Neutrophil

Potential of GSPT1 as a novel target for glioblastoma therapy

Triptolide inhibits the progression of Glioblastoma U251 cells via targeting PROX1

Loss of PTPRS elicits potent metastatic capability and resistance to temozolomide in glioblastoma

Downregulation of SNRPG induces cell cycle arrest and sensitizes human glioblastoma cells to temozolomide by targeting Myc through a p53-dependent signaling pathway

TMEM60 Promotes the Proliferation and Migration and Inhibits the Apoptosis of Glioma Through Modulating AKT Signaling

Knockdown of DEPDC1B inhibits the development of glioblastoma

Invadopodia associated Thrombospondin-1 contributes to a post-therapy pro-invasive response in glioblastoma cells